FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Edesa Biotech's Free Cash Flow for the
three
months ended in Dec. 2024 was $-1.52 Mil. Edesa Biotech's Revenue for the
three
months ended in Dec. 2024 was $0.00 Mil. Therefore, Edesa Biotech's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.
The historical rank and industry rank for Edesa Biotech's FCF Margin % or its related term are showing as below:
During the past 13 years, the highest FCF Margin % of Edesa Biotech was -385.85%. The lowest was -2358.02%. And the median was -1353.43%.
EDSA's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -139.165 * Ranked among companies with meaningful FCF Margin % only.
Edesa Biotech FCF Margin % Historical Data
The historical data trend for Edesa Biotech's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Edesa Biotech's FCF Margin %
For the Biotechnology subindustry, Edesa Biotech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edesa Biotech's FCF Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Edesa Biotech's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Edesa Biotech's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edesa Biotech FCF Margin % Related Terms
Thank you for viewing the detailed overview of Edesa Biotech's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EDSA has been successfully added to your 